Billions of doses of coronavirus disease 2019 (COVID-19) vaccines have been administered
globally, dramatically reducing severe acute respiratory syndrome coronavirus 2 (SARS …

Background Immune responses on SARS-CoV-2 vaccination in patients receiving anti-
CD20 therapies are impaired but vary considerably. We conducted a systematic review and …

Background Before the emergence of the B. 1.617. 2 (delta) variant of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), vaccination reduced transmission of …

SARS-CoV-2 vaccines are crucial in controlling COVID-19, but knowledge of which factors
determine waning immunity is limited. We examined antibody levels and T-cell gamma …

The effectiveness of the BNT162b2 and ChAdOx1 vaccines against new severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infections requires continuous re …

Population antibody surveillance helps track immune responses to COVID-19 vaccinations
at scale, and identify host factors that may affect antibody production. We analyse data from …

Background Most studies of immunity to SARS-CoV-2 focus on circulating antibody, giving
limited insights into mucosal defences that prevent viral replication and onward …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine immunogenicity
varies between individuals, and immune responses correlate with vaccine efficacy. Using …

Objective The purpose of this study was to investigate the effect of disease modifying
therapies on immune response to severe acute respiratory syndrome‐coronavirus 2 (SARS …

The UK prioritised delivery of the first dose of BNT162b2 (Pfizer/BioNTech) and AZD1222
(AstraZeneca) vaccines by extending the interval between doses up to 12 weeks. In 750 …